Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Survey of activated FLT3 signaling in leukemia.

PloS one - 28 Apr 2011

Gu Ting-lei, Nardone Julie, Wang Yi, Loriaux Marc, Villén Judit, Beausoleil Sean, Tucker Meghan, Kornhauser Jon, Ren Jianmin, MacNeill Joan, Gygi Steven P, Druker Brian J, Heinrich Michael C, Rush John, Polakiewicz Roberto D

Abstract excerpt

Activating mutations of FMS-like tyrosine kinase-3 (FLT3) are found in approximately 30% of patients with acute myeloid leukemia (AML). FLT3 is therefore an attractive drug target. However, the molecular mechanisms by which FLT3 mutations lead to cell transformation in AML remain unclear. To deve...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow Cells
Share to Cell Line, Tumor
Share to fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Phosphorylation

Share to Piperazines

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to Quinazolines

Source

Open in PubMed Open full text

Identifiers

PMID: 21552520
DOI: 10.1371/journal.pone.0019169
PMCID: PMC3084268

Genes

FLT3
BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-21552520-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Survey of activated FLT3 signaling in leukemia.PMID 21552520Read ↗

Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemiaSemantic proximity Read ↗

Phosphotyrosine-based Phosphoproteomics for Target Identification and Drug Response Prediction in AML Cell Lines.Semantic proximity Read ↗

Structural and functional alterations of FLT3 in acute myeloid leukemia.Semantic proximity Read ↗

Phosphoproteome analyses reveal specific implications of Hcls1, p21-activated kinase 1 and Ezrin in proliferation of a myeloid progenitor cell line downstream of wild-type and ITD mutant Fms-like tyrosine kinase 3 receptors.Semantic proximity Read ↗

Normal and oncogenic FLT3.Semantic proximity Read ↗

Role of Biomarkers in FLT3 AMLSemantic proximity Read ↗

Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategiesSemantic proximity Read ↗

The role of FLT3 kinase as an AML therapy target.Semantic proximity Read ↗

A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patientsSemantic proximity Read ↗

SYK is a critical regulator of FLT3 in acute myeloid leukemia.Semantic proximity Read ↗

Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemiaSemantic proximity Read ↗

FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.